The nation of Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's demand for sensitive data.
The decision became public after a government memo dated December was disclosed, which showed President Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesman has since explained that the US was demanding access to genetic material for research and commercial purposes while refused to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable task of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more negotiations to find a agreement agreeable to all parties so the nation's critical HIV treatment initiative can be sustained.
Broader Background
This rejection follows a comparable situation in neighbouring Kenya, where a court suspended a related health funding agreement after concerns were filed about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and accountability.
According to statements, 16 African countries have to date signed similar agreements, representing more than $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no equivalent promise of access to any medical innovations – such as new medicines or tests – that might result from that shared data," he stated.
"In essence, our country would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our citizens if a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its push of bilateral health agreements were upending systems previously set up through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how future co-operation might be arranged in a manner that respects the sovereignty and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but suggested that negotiations need to persist considering much of the country's HIV programmes depended on foreign aid.
"If technical issues arise, including those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it said.
The situation underscores the complex debate between receiving much-needed international aid and safeguarding a country's data in an increasingly data-driven world.